ArticleTranslational cancer research2026
Overexpression of ACTL6A is associated with poor prognosis in gastric cancer, and nuclear level is an independent predictor.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is a heterogeneous disease with limited prognostic biomarkers. ACTL6A is a core subunit of chromatin remodeling complexes, is implicated in tumor progression, but its clinical relevance, particularly subcellular localization, in GC remains unclear. This study aims to investigate whether the subcellular distribution of ACTL6A can serve as a potential biomarker for prognosis assessment in patients with GC. Methods: Multi-platform bioinformatics analysis of public datasets (The Cancer Genome Atlas, Genotype-Tissue Expression, DepMap) was performed to evaluate the expression of ACTL6A in GC. Western blot was employed to assess ACTL6A protein expression in GC cell lines. ACTL6A protein expression and localization were further evaluated by immunohistochemistry (IHC) in a tissue microarray (TMA) cohort of 96 GC patients, including 96 cases of GC tissues and 84 cases of normal adjacent tissues. The associations of clinicopathological features and overall survival (OS) were analyzed by univariate Cox regression and multivariate Cox regression. After knockdown of ACTL6A, the migration and invasion abilities of GC cells were observed, and protein-protein interaction networks were constructed. Results: ACTL6A was significantly overexpressed at messenger RNA (mRNA) and protein levels in GC versus normal tissue. High ACTL6A expression positively correlated with advanced N stage (lymph node metastasis). Crucially, high nuclear (but not cytoplasmic) ACTL6A protein expression was an independent and powerful prognostic factor in GC. The hazard ratio (HR) is 3.052, with a 95% confidence interval (CI) of 1.643-5.670, and P<0.001. Moreover, after knockdown of ACTL6A, the migration and invasion abilities of GC cells were weakened. Conclusions: Nuclear ACTL6A is a compartment-specific, independent prognostic biomarker in GC, associated with lymph node metastasis and poor survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.